These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35379264)

  • 21. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.
    Ballas LK; Luo C; Chung E; Kishan AU; Shuryak I; Quinn DI; Dorff T; Jhimlee S; Chiu R; Abreu A; Jennelle R; Aron M; Groshen S
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):50-60. PubMed ID: 30605751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial.
    Gregucci F; Carbonara R; Surgo A; Ciliberti MP; Curci D; Ciocia A; Branà L; Ludovico GM; Scarcia M; Portoghese F; Caliandro M; Ludovico E; Paulicelli E; Di Guglielmo FC; Bonaparte I; Fiorentino A
    Radiol Med; 2023 Apr; 128(4):501-508. PubMed ID: 36952115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
    Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial.
    Maas JA; Dobelbower MC; Yang ES; Clark GM; Jacob R; Kim RY; Cardan RA; Popple R; Nix JW; Rais-Bahrami S; Fiveash JB; McDonald AM
    Pract Radiat Oncol; 2023; 13(5):466-474. PubMed ID: 37268193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
    Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
    BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial.
    Zilli T; Franzese C; Guckenberger M; Giaj-Levra N; Mach N; Koutsouvelis N; Achard V; Mcdonald A; Alongi F; Scorsetti M; Constantin G; Bertaut A; Miralbell R
    Radiother Oncol; 2024 May; 194():110181. PubMed ID: 38403022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
    Rucinska M; Kieszkowska-Grudny A; Nawrocki S
    Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
    Deodato F; Ferro M; Bonome P; Pezzulla D; Romano C; Buwenge M; Cilla S; Morganti AG; Macchia G
    Strahlenther Onkol; 2024 Mar; 200(3):239-249. PubMed ID: 38180492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer.
    Potters L; Rana Z; Lee L; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):334-342. PubMed ID: 30721721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.
    Ugurluer G; Atalar B; Zoto Mustafayev T; Gungor G; Aydin G; Sengoz M; Abacioglu U; Tuna MB; Kural AR; Ozyar E
    Br J Radiol; 2021 Jan; 94(1117):20200696. PubMed ID: 33095670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) Glands.
    Hurwitz JC; Haas J; Mendez C; Sanchez A; Santos VF; Akerman M; Carpenter T; Tam M; Katz A; Corcoran A; Mahadevan A; Taneja SS; Lepor H; Lischalk JW
    Pract Radiat Oncol; 2024; 14(3):241-251. PubMed ID: 37984713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
    Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
    Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
    Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
    Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiotherapy for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    BMC Urol; 2010 Feb; 10():1. PubMed ID: 20122161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
    Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
    Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
    Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
    Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
    Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial.
    Sampath S; Frankel P; Vecchio BD; Ruel N; Yuh B; Liu A; Tsai T; Wong J
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):537-545. PubMed ID: 31733323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results.
    Zilli T; Jorcano S; Bral S; Rubio C; Bruynzeel AME; Oliveira A; Abacioglu U; Minn H; Symon Z; Miralbell R
    Cancer Med; 2020 May; 9(9):3097-3106. PubMed ID: 32160416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients.
    Ishiyama H; Tsumura H; Nagano H; Watanabe M; Mizuno E; Taka M; Kobayashi H; Eriguchi T; Imada H; Inaba K; Nakamura K
    Sci Rep; 2021 Jun; 11(1):13194. PubMed ID: 34162908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.